Drug Information Association Logo

DIA to Shine Light on Newly Released PCAST Report

WASHINGTON — Apr 17, 2013

“Reinventing the R&D Business Model: Heeding the President’s PCAST Report on Innovation” to Be Hosted by the Tufts Center for the Study of Drug Development

A consummate group of moderators and panelists will participate in an executive session at DIA’s 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science. The session, to be held on June 25 in Boston, will be hosted by the Tufts Center for the Study of Drug Development (CSDD) and focus on a report released in January by the President’s Council of Advisors on Science and Technology (PCAST). Included in the panel will be Bernard Munos, founder of InnoThink Center for Research in Biomedical Innovation, who was recently noted in FierceBiotech as one of the 25 most influential people in biopharma, and Dalvir Gill, CEO of TransCelerate Biopharma Inc.

With the landscape for biopharmaceuticals rapidly changing, this senior-level session will examine how companies across the pharmaceutical sector are transforming their R&D business models to meet current and future market demands. Along with R&D, the panel will address preclinical, clinical, regulatory, operations, portfolio management and marketing issues—all aspects of business development.

Susan Cantrell, director of DIA North America, said, “We are truly honored to have this panel, whose members bring unparalleled experience, expertise and thought leadership. With the insight of these esteemed panelists, we are certain this interactive session will provide invaluable information that will help companies to move their businesses forward. Their views and discussion of the PCAST report come at an exciting time as the country seeks to lead the world in health care innovation.”

The moderators and panelists include:

  • Kenneth I. Kaitin, Ph.D.
    Professor and Director, CSDD
    Tufts University School of Medicine 
  • Kenneth A. Getz, MBA
    Director of Sponsored Research, Tufts CSDD; Chairman, Center for Information and Study on Clinical Research Participation
    Tufts University
    DIA Chairman, 2011
  • Bernard Munos, MBA
    InnoThink Center for Research in Biomedical Innovation
  • Tomasz Sablinski, M.D.
    Founder and CEO
    Transparency Life Sciences
  • Robert J. Franco, Ph.D.
    PricewaterhouseCoopers LLP
  • Andy Lee, M.D.
    Senior Vice President, Global Clinical Operations
  • Dalvir Gill, Ph.D.
    TransCelerate Biopharma Inc.

Visit www.diahome.org/DIA2013 to learn more about DIA’s 2013 49th Annual Meeting.






ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.